Home › Compare › ASROF vs ABBV
ASROF yields 210.11% · ABBV yields 3.06%● Live data
📍 ASROF pulled ahead of the other in Year 1
Combined, ASROF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ASROF + ABBV for your $10,000?
Astrocast SA, an Internet of Things (IoT) focused nanosatellite company, provides satellite IoT connectivity services to track, monitor, manage, and communicate with assets in remote regions worldwide. Its products portfolio includes the Astronode S, a bidirectional satellite communication module for connecting IoT devices to the Astrocast nanosatellite network; Astronode S+, a ready-to-install satellite communication device; Astronode DevKit, which has the Astronode S architecture that enables to connect your assets to the Astrocast nanosatellite network; and Patch Antenna, a miniaturized antenna designed for communication with Astrocast's constellation of IoT satellites in LEO. The company also offers Astrocast Portal that allows customers to manage their Astronode S modules and devices through a web application; and Astrocast API, which allows customers to manage their Astronode S modules and devices, retrieve messages received from their assets, and send commands back through a secure REST API built on standard JSON messages. It serves various industries, such as agriculture and livestock; environment and utilities; maritime; land transport; mining; and oil and gas. Astrocast SA was incorporated in 2014 and is based in Chavannes-Renens, Switzerland.
Full ASROF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.